Dapagliflozina Perioperatoria para Mejorar los Resultados de la Cirugía Cardíaca en Pacientes con Diabetes Tipo 2

Sodium-Glucose Cotransporter 2 Inhibitors, such as dapagliflozin, are commonly used for treating type 2 diabetes. Recent findings suggest that these inhibitors not only lower blood sugar but also protect the heart and kidneys, improving patients' quality of life significantly. However, patients with type 2 diabetes often have poorer outcomes after heart surgery compared to those without diabetes. This study explores whether using dapagliflozin around the time of surgery can improve post-surgery outcomes in type 2 diabetes patients undergoing heart surgery. This is a randomized controlled trial where participants receive dapagliflozin before and after surgery. The study measures the effects of dapagliflozin by monitoring high sensitive cardiac troponin-I levels, a protein that indicates heart damage. The primary goal is to determine if dapagliflozin can reduce heart damage associated with heart surgery in type 2 diabetes patients.